Evaluation of C-C Motif Chemokine Receptor 5 (CCR5) as a Sample Adequacy Control in HPV Molecular Diagnostics
Authors:
- Ruth Chinyere NjokuRNRuth Chinyere Njoku
- Marianna MartinelliMMMarianna Martinelli
- Chiara GiubbiCGChiara Giubbi
- Sofia De MarcoSMSofia De Marco
- Barbara TorselloBTBarbara Torsello
- Morena D'AveniaMDMorena D'Avenia
- Manuela SironiManuela Sironi
- Cristina BianchiCBCristina Bianchi
- Clementina Elvezia CocuzzaCCClementina Elvezia Cocuzza
Preprint
- 5 September 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background: Reliable HPV testing and genotyping are essential for quality assurance in HPV-based primary screening, disease management and for monitoring the impact of HPV vaccination. The clinical validation of HPV molecular diagnostic assays has significantly contributed to these objectives, however little emphasis has been placed in assuring sample quality. This study aims to assess the accuracy of sample cellularity assessment using C-C Motif Chemokine Receptor 5 (CCR5) gene target as a marker of sample adequacy in molecular diagnostics. Methods: Jurkat cell line samples were counted both using Thoma cell-counting chamber and Fluorescent-Activated Cell Sorting (FACS). Jurkat cell line samples at three different concentrations were subsequently evaluated using the OncoPredict HPV Quality Control (QC) real-time PCR assay, employing CCR5 for molecular cellularity quantification. Results: Cellularity values obtained were comparable across the 3 different methods for all dilutions of the cell line tested. Conclusions: The results obtained from this study show that CCR5 represents a promising molecular marker for the accurate quantification of sample cellularity, confirming its use as a reliable sample adequacy control, thus reducing the risk of “false negative” results.Keywords
All Related Versions
- Version 1, 2024-09-05, Preprints
- Published version: Diagnostics, 14 (19), 2194.
This publication has 44 references indexed in Scilit:
- Human papillomavirus testing using HPV APTIMA® assay and an external cellularity control in self‐collected samplesJournal of Medical Virology, 2023
- Clinical performance of the novel full‐genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT frameworkInternational Journal of Cancer, 2023
- Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT‐2 frameworkJournal of Medical Virology, 2022
- 2020 list of human papillomavirus assays suitable for primary cervical cancer screeningClinical Microbiology and Infection, 2021
- hrHPV prevalence and type distribution in rural Zimbabwe: A community-based self-collection study using near-point-of-care GeneXpert HPV testingInternational Journal of Infectious Diseases, 2019
- Evaluation of self-collected vaginal specimens for the detection of high-risk human papillomavirus infection and the prediction of high-grade cervical intraepithelial lesions in a high-burden, low-resource settingClinical Microbiology and Infection, 2019
- Direct comparison of two vaginal self-sampling devices for the detection of human papillomavirus infectionsJournal of Clinical Virology, 2016
- VALGENT: A protocol for clinical validation of human papillomavirus assaysJournal of Clinical Virology, 2016
- EUROGIN 2011 roadmap on prevention and treatment of HPV‐related diseaseInternational Journal of Cancer, 2012
- Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and olderInternational Journal of Cancer, 2008